Register and share your invite link to earn from video plays and referrals.

Search results for NOVAバー です!
NOVAバー です! community
One keyword maps to one global community path.
Create community
People
Not Found
Tweets including NOVAバー です!
NOVA Blueprint Update: Nesso-1 & Antitarget Scoring We’re upgrading NOVA Blueprint with Nesso-1 as its new oracle model, replacing Boltz-2, and reintroducing antitarget scoring to reward molecules with stronger predicted binding selectivity. Why it matters: • Higher throughput: Nesso-1 enables significantly faster binding affinity predictions, allowing miners to evaluate more molecules and explore chemical space more efficiently within the same competition time budget. • Greater selectivity: Reintroducing two antitarget proteins encourages algorithms to identify molecules that bind strongly to the intended target while minimizing predicted binding to undesired proteins. The first competition will establish a new champion in a single round, with a bounty capped at one day’s emissions. Standard competition rules resume afterward. The oracle is open source, so miners can run their own benchmarks and testing. We’ll also publish performance metrics for our selected hardware. Rollout: November 9 | Epoch 20767 Code available for review: Oracle: Blueprint:
Show more
NOVA: Emission Split Update for Data Generation Fund Owner 26% / Miners 33% / Validators 41% With the launch of eTAO, subnet owners can now adjust how emissions are distributed. NOVA will be updating its split to allocate more resources toward what we believe is the highest-impact investment we can make in the subnet's future: experimental data generation. Wet lab data is the best investment we can make both to prove out what the subnet produces and to increase the value of what gets built on top of it. Data is the bottleneck AI-driven drug discovery faces a fundamental constraint: the quality of our predictions is ultimately limited by the experimental data available to train and validate them. Much of today's publicly available drug discovery data is fragmented across studies, generated using different experimental protocols, and inconsistent in quality and coverage. Generating high-quality experimental data allows us to address that limitation directly. It gives miners better ground truth for model development, provides independent validation of their predictions, and helps us identify which approaches actually translate into experimental success. The industry is making the same bet. Some of the largest investments in AI-driven biology are now directed toward generating the experimental data necessary to train and validate better models. Biohub committed $400M of a $500M, five-year initiative to data generation, infrastructure and measurement technology, and later expanded into a $1.8B effort backed by Meta, Google DeepMind and Isomorphic Labs, who collectively committed $300M. The OpenAI Foundation gave $15M to OpenADMET to generate public ADME datasets, which will be used in prospective blind challenges against newly measured experimental data. Octant continues the high-throughput data generation behind it. Leash Bio used a $9.3M seed round to scale data collection for a foundational medicinal chemistry model, producing a dataset that screened 133 million molecules against each protein. Anthropic has set up a physical biology lab in the Bay Area. What the additional funds will support The additional owner allocation will go into a dedicated R&D fund for wet lab data generation. 1. ADME model training competition. The first use of the fund is generating the experimental data behind our ADME competition, currently in design and development. High-quality, standardized ADME data is what turns a competition from a benchmark into something that produces models with real predictive value. 2. Advancing assets under development. Where it makes sense, the fund can also support experimental work that moves our in-development assets forward. Why this benefits the entire NOVA ecosystem We believe generating experimental data is one of the most effective ways to increase the long-term value of the subnet. For miners, better datasets and scientifically grounded evaluations create opportunities to develop more capable models, compete on meaningful performance improvements, and contribute work with greater real-world utility. For validators, stronger experimental benchmarks improve the ability to assess model quality and reward useful contributions. For tokenholders, better models, experimentally validated discoveries, and progress toward valuable therapeutic assets can strengthen NOVA's competitive position and long-term commercial potential. The economic opportunity extends beyond any individual competition. We are building an increasingly capable scientific discovery platform, and the data generated through our R&D efforts can become a compounding asset for the entire ecosystem. Miner incentives remain strong Miners will still receive a meaningfully larger share than the owner (33% vs. 26%), and we believe the rewards will preserve healthy, competitive incentives for participation. Better data and better-validated competitions also make the work miners do more valuable over time. Protecting token health Funds from the R&D allocation will be converted to cover lab costs gradually, distributed over time rather than sold in size, to limit market impact and preserve token health. The bottom line We think this is the single best thing we can do to accelerate our progress, increase our chance of success, and create value for everyone with a stake in NOVA, including miners, validators, and tokenholders. It is time for us to scale real-world validation.
Show more
NOVA Hit-to-Lead Optimization Agent In collaboration with @chutes_ai and @onepot_ai We're developing a Hit-to-Lead optimization agent that integrates an algorithm developed by a NOVA Blueprint winner, extending NOVA's capabilities beyond hit discovery and into the iterative optimization of small molecules. The system combines a domain-specialized AI agent with proprietary combinatorial chemical databases supplied by our partner Onepot AI, spanning billions of possible compounds, that are delivered within 5-7 business days. Researchers will be able to guide the agent in developing, comparing and refining optimization strategies, exploring chemical modifications and prioritizing candidates based on predicted affinity, selectivity, physicochemical properties and specific binding interactions. Confidentiality is a central design requirement. Pharmaceutical R&D involves valuable intellectual property, including compound structures, targets, emerging chemical series and optimization strategies that cannot be exposed publicly. The Chutes team integrated domain specific models so that we can run inference in their verified Trusted Execution Environments (TEEs), with encrypted communication and controlled access to proprietary databases and project records. This architecture is intended to support confidential inference on external infrastructure while preserving organizational control over sensitive research data. Finding a molecule with promising predicted affinity is only the beginning. Hit-to-Lead optimization involves balancing multiple, often competing objectives, including potency, selectivity, physicochemical properties and synthesizability, before progressing toward experimental activity and ADME validation. The next step is to integrate the agent into our own Hit-to-Lead development program. For NOVA, this represents an important step toward translating algorithms developed through open competition into tools for proprietary drug discovery programs, including our own asset-development pipeline and those of external research partners.
Show more
Nova toons is live on @AppStore If you have not opened Nova Toons lately, start there. Original stories and partner IP are already live, including Shibamaru: The Demon Samurai with @shibtoken and the WIF & the Sphere Heist with @dogwifcoin. The update: the Nova Toons Creator Economy will be announced very soon. This is the layer where creators earn from the work they publish, and where platform revenue is routed back into the ecosystem. A share of that revenue is designed to fund organic $RVV buybacks from the open market. Not a one-off. A repeatable loop tied to real usage. That is the point of the Creator Economy. Content is not only engagement. It becomes a demand engine for $RVV. Full mechanics drop with the announcement. Do not sit this one out. Read now:
Show more
Nova Scotia’s new EV and PHEV levies start October 1
Nova's Naked Aurora Ride On The Frozen Lake 🎬 🎬 #aibabe# #aigirl# #aiwaifu# #aiporn# #aigenerated# #nsfwai# #hentai# #rule34# #nsfw# #porn# #xxx# #lewd# #adultcontent# #pov#
Show more
NOVA Blueprint Update: The Triple Crown We’re improving the blueprint’s winner selection mechanism to better reward strong, generalizable performance. Previously, a challenger could replace the current king by clearing the winning threshold in a single epoch. Under the new **Triple Crown** system, a challenger must clear the threshold across **three consecutive epochs**, each with a **different target**. The update is intended to: * Reward improvements that are robust and repeatable * Encourage stronger generalization across targets * Increase confidence that a new winner represents a meaningful step forward * Make successful takeovers more representative of sustained performance To take the crown, a challenger must now earn it three times against the previous best. You can review the implementation here:
Show more
'Nova Knicks cement their legend with NBA title: 'Brothers for life'
Nova Knicks stay winning 🏆 Ten years after winning it all at Villanova, Brunson, Hart and Bridges are champions together again!
0
96
6.3K
904
Forward to community
NOVA Conviction Update + Incentive Alignment We didn't choose drug discovery because it was an easy or fast problem to solve. We chose it because it's one of the hardest and most meaningful problems AI can tackle. Our ambition and track record reflects our commitment to long-term value creation. Since launching, NOVA has shipped 3 incentive mechanisms, established 3 relevant partnerships with other biotech companies outside of the Bittensor ecosystem, provided open-source access to optimized and fine-tuned SOTA models, run ongoing screening campaigns across multiple therapeutic modalities, and much more. That work has been funded by token sales and it will continue on multi-year timelines regardless of short-term price action. As the conviction mechanism rolls out across Bittensor, we want to be transparent about how we're approaching it by locking company tokens and aligning founder incentives with subnet growth. Company Wallet — 50% Locked Even before conviction, we've always balanced self-financing with token health. We locked 50% of our company tokens formalizing that commitment (and we’re one of the top subnets in % and TAO equivalent). From here, the owner's cut will be automatically locked so our conviction will only grow over time. The liquid 50% funds operations through token sales and OTC, and gives us flexibility to navigate price volatility. We will continue to minimize price impact and optimize for token health. Founder Incentive Alignment We're allocating 20% of what we earn split across the four founders as a direct incentive. Each founder has real skin in the game, individually motivated to grow NOVA. Based on the current wallet distribution, each founder's individual position will remain below the top 10 holders after tax. This distribution naturally decentralizes stake across the team. Our upside is tied directly to yours. Built for the Long Term We came to Bittensor to build infrastructure that accelerates drug discovery. The problems we're solving have the potential to reshape how medicine is made with multi-year timelines and billions in implications. Long term thinking is baked into everything we do. Long-term thinking is baked into everything we do. We remain focused on: • building valuable discovery systems • advancing therapeutic development • expanding partnerships • improving incentive mechanisms • and creating lasting value for the network Thank you to everyone helping us build. This is only the beginning.
Show more